AstraZeneca MYSTIC Read-Out Delay Further Boost To Merck
Overall survival data are now not due until the second half of the year but however they turn out competitor Merck & Co is still expected to dominate the late-stage NSCLC market with Keytruda.
You may also be interested in...
Failure of the ARCTIC study was considered likely and will do little to dent Imfinzi's overall sales prospects but cools sentiment on the CTLA4 inhibitor tremelimumab.
Data showing overall survival benefit for Keytruda in patients with at least 1% PD-L1 expression ups the ante for competitors Bristol and Roche, which will be presenting data for combinations in lung cancer at the American Association of Clinical Research meeting in April.
Unlike other indications PD-1/L1 inhibitors are shooting for, Stage III non-small cell lung cancer is an untapped market and AstraZeneca will have the space to itself for a while.